NASDAQ:RXRX Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis $3.58 -0.06 (-1.65%) Closing price 10/22/2026 04:00 PM EasternExtended Trading$3.54 -0.04 (-0.98%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Recursion Pharmaceuticals Stock (NASDAQ:RXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RXRX alerts:Sign Up Key Stats Today's Range$3.49▼$3.6850-Day Range$3.09▼$4.7852-Week Range$2.77▼$6.50Volume17.70 million shsAverage Volume30.76 million shsMarket Capitalization$1.92 billionP/E RatioN/ADividend YieldN/APrice Target$8.18Consensus RatingHold Company Overview Recursion Pharmaceuticals, Inc. is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments. Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases. The company develops selected drug candidates internally and also works with pharmaceutical and biotechnology partners to use its technology for target discovery, compound design and preclinical research. Its pipeline has included programs based on both new and existing therapeutic approaches. Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion operates as a technology-enabled drug discovery company serving global pharmaceutical and biotechnology markets. In 2024, it completed a combination with Exscientia plc, another company focused on artificial intelligence-driven drug design, expanding its capabilities in computational chemistry and automated discovery. Recursion was co-founded and is led by Chief Executive Officer Christopher D. Gibson.AI Generated. May Contain Errors. Read More Recursion Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreRXRX MarketRank™: 3.109137055835 of 5 starsRecursion Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 318th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingRecursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialRecursion Pharmaceuticals has a consensus price target of $8.18, representing about 128.5% upside from its current price of $3.58.Amount of Analyst CoverageRecursion Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Recursion Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Recursion Pharmaceuticals are expected to grow in the coming year, from ($0.93) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Recursion Pharmaceuticals is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recursion Pharmaceuticals is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRecursion Pharmaceuticals has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Recursion Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted31.60% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 6.13.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently decreased by 11.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRecursion Pharmaceuticals does not currently pay a dividend.Dividend GrowthRecursion Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.49 News SentimentRecursion Pharmaceuticals has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Recursion Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest37 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.MarketBeat Follows24 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Recursion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $643,576.00 in company stock.Percentage Held by Insiders6.65% of the stock of Recursion Pharmaceuticals is held by insiders.Percentage Held by Institutions89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Recursion Pharmaceuticals' insider trading history. Receive RXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RXRX Stock News HeadlinesRecursion Pharmaceuticals (NASDAQ:RXRX) Given Buy Rating at Needham & Company LLCOctober 19, 2026 | americanbankingnews.comRecursion Pharmaceuticals (RXRX) Reached A $10 Million Immunology MilestoneOctober 18, 2026 | finance.yahoo.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Recursion Pharmaceuticals, Inc. (RXRX) - What Are Researchers Saying About This Stock?October 18, 2026 | americanbankingnews.comMorgan Stanley Remains a Hold on Recursion Pharmaceuticals (RXRX)October 17, 2026 | theglobeandmail.comRecursion Pharmaceuticals (NASDAQ:RXRX) Upgraded to "Sell" at Wall Street ZenOctober 17, 2026 | americanbankingnews.comRXRX stock heads for its best day in over a year – what's driving the rally today?October 16, 2026 | msn.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 25,000 Shares of StockOctober 8, 2026 | insidertrades.comSee More Headlines RXRX Stock Analysis - Frequently Asked Questions How have RXRX shares performed this year? Recursion Pharmaceuticals' stock was trading at $4.09 at the beginning of 2026. Since then, RXRX shares have decreased by 12.5% and is now trading at $3.58. How were Recursion Pharmaceuticals' earnings last quarter? Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.01. The company earned $7.67 million during the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative trailing twelve-month return on equity of 50.41%. Read the conference call transcript. When did Recursion Pharmaceuticals IPO? Recursion Pharmaceuticals (RXRX) raised $412 million in an IPO on Thursday, April 15th 2021. The company issued 24,242,424 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO. Who are Recursion Pharmaceuticals' major shareholders? Top institutional investors of Recursion Pharmaceuticals include Green Alpha Advisors LLC (0.04%), SBI Securities Co. Ltd. (0.03%), TD Waterhouse Canada Inc. (0.01%) and Whalen Wealth Management Inc. (0.01%). Insiders that own company stock include Blake Borgeson, Najat Khan, Michael Secora, Ben R Taylor, Christopher Gibson, Tina Marriott, Dean Y Li, Tina Marriott Larson, Robert Hershberg, Shafique Virani, Namandje Bumpus and Zavain Dar. View institutional ownership trends. How do I buy shares of Recursion Pharmaceuticals? Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Recursion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), SoundHound AI (SOUN), Tesla (TSLA), Micron Technology (MU) and IonQ (IONQ). Company Calendar Last Earnings8/05/2026Today10/23/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, RXRX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RXRX CIK1601830 Webwww.recursion.com Phone385-269-0203Fax801-821-2872Employees600Year Founded2013Price Target and Rating Average Price Target for Recursion Pharmaceuticals$8.18 High Price Target$11.00 Low Price Target$5.90 Potential Upside/Downside+128.5%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$644.76 million Net Margins-945.94% Pretax Margin-954.29% Return on Equity-50.41% Return on Assets-38.25% Debt Debt-to-Equity Ratio0.01 Current Ratio5.03 Quick Ratio5.03 Sales & Book Value Annual Sales$74.68 million Price / Sales25.66 Cash FlowN/A Price / Cash FlowN/A Book Value$2.14 per share Price / Book1.67Miscellaneous Outstanding Shares535,340,000Free Float499,742,000Market Cap$1.92 billion OptionableOptionable Beta1.04 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:RXRX) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
